These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36091003)

  • 41. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
    Gou M; Zhang Y; Wang Z; Qian N; Dai G
    Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.
    Liu D; Mu H; Liu C; Zhang W; Cui Y; Wu Q; Zhu X; Fang F; Zhang W; Xing W; Li Q; Song T; Lu W; Li H
    Neoplasma; 2023 Dec; 70(6):811-818. PubMed ID: 38247334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma.
    Wang H; Zhu X; Zhao Y; Dong D; Li L; Cai Y; Li Y; Wang W
    BMC Cancer; 2022 Jul; 22(1):771. PubMed ID: 35840914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
    Yuan GS; He WM; Hu XY; Li Q; Zang MY; Cheng X; Huang W; Ruan J; Wang JJ; Hou JL; Chen JZ
    Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):326-331. PubMed ID: 33979958
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy and biomarker exploration of camrelizumab combined with apatinib in the treatment of advanced primary liver cancer: a retrospective study.
    Zeng Z; Jiang Y; Liu C; Zhu G; Ma F; Yang L; Qiu J; Tang J; Ye X; Peng T; Zeng J; Ma J
    Anticancer Drugs; 2021 Nov; 32(10):1093-1098. PubMed ID: 34232941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
    Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
    Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
    Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
    Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.
    Tang Z; Wang Y; Yu Y; Cui Y; Liang L; Xu C; Shen Z; Shen K; Wang X; Liu T; Sun Y
    BMC Med; 2022 Apr; 20(1):107. PubMed ID: 35382819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.
    Wang K; Xiang YJ; Yu HM; Cheng YQ; Liu ZH; Qin YY; Shi J; Guo WX; Lu CD; Zheng YX; Zhou FG; Yan ML; Zhou HK; Liang C; Zhang F; Wei WJ; Lau WY; Li JJ; Liu YF; Cheng SQ
    Nat Med; 2024 Mar; 30(3):708-715. PubMed ID: 38242982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial.
    Chen S; Wang X; Yuan B; Peng J; Zhang Q; Yu W; Ge N; Weng Z; Huang J; Liu W; Wang X; Chen C
    Nat Commun; 2024 Oct; 15(1):8857. PubMed ID: 39402023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial.
    Wang Y; Zhao J; Liang H; Liu J; Huang S; Zou G; Huang X; Lan C
    EClinicalMedicine; 2023 Nov; 65():102274. PubMed ID: 38106561
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
    Changou CA; Shiah HS; Chen LT; Liu S; Luh F; Liu SH; Cheng YC; Yen Y
    Oncologist; 2021 Mar; 26(3):e367-e373. PubMed ID: 33140457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.
    Lu F; Zhao K; Ye M; Xing G; Liu B; Li X; Ran Y; Wu F; Chen W; Hu S
    BMC Cancer; 2024 Aug; 24(1):1023. PubMed ID: 39160484
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
    Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
    Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.